000 02305cam a2200349 a 4500
003 EG-GiCUC
005 20250223032157.0
008 190131s2018 ua dh f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.11.07.Ph.D.2018.Em.A
100 0 _aEman Ahmed Youssef
245 1 0 _aAssessment of the role of NOGO gene block in enhancing the neuro-regenerative effect of mesenchymal stem cells /
_cEman Ahmed Youssef ; Supervised Hala Gabr , Reham Afeefy , Nirmeen Adel
246 1 5 _aفي تعزيز تأثير التجدد العصبي للخلايا الجذعية الوسيطة NOGO تقييم دور إسكات كتلة الجين
260 _aCairo :
_bEman Ahmed Youssef ,
_c2018
300 _a238 P. :
_bcharts , facsimiles ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
520 _aAim: Amyotrophic Lateral Sclerosis (ALS) is a fatal disease. Mesenchymal stem cells (MSCs) have a therapeutic potential in neuronal diseases, factors as NOGO A limit the axonal regeneration. In this study, gene silencing was used to suppress Nogo-A expression in MSCs, augmenting their neuro-regenerative role. Methods: MSCs were cultured from mice bone marrow then transfected with a plasmid coding for NOGO-A gene SiRNA, mouse models of motor neuron degeneration were created, therapeutic role of non-modified and plasmid transfected MSCs were studied and assessed clinically and histologically. Group 1 mice received no treatment. Group 2 received an IV injection of non modified MSCs and sacrificed 8 days (subgroup 2a) and 15 days (subgroup 2b) following treatment, Group 3 received an IV injection of transfected MSCs and were sacrificed 8 days (subgroup 3a) and 15 days (subgroup 3b) following treatment
530 _aIssued also as CD
653 4 _aAmyotrophic Lateral Sclerosis (ALS)
653 4 _aMesenchymal stem cells (MSCs)
653 4 _aNeuroregeneration
700 0 _aHala Gabr,
_eSupervisor
700 0 _aNirmeen Adel ,
_eSupervisor
700 0 _aReham Afeefy ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aShimaa
_eCataloger
942 _2ddc
_cTH
999 _c69879
_d69879